Roivant Sciences Q4 Income $355.7M; $2.25B Moderna Settlement
Roivant Sciences reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, highlighted by a significant $2.25 billion global settlement with Moderna. The company achieved income from continuing operations, net of tax, of $355.7 million for the quarter, largely driven by the litigation settlement gain. Roivant also provided positive business updates, including strong clinical trial data for IMVT-1402, Breakthrough Therapy Designation for brepocitinib, and several upcoming commercial launches and clinical readouts, while maintaining a strong cash position of $4.3 billion.
Key Highlights
- $2.25 billion global settlement reached with Moderna, with $950 million non-contingent payment due July 2026.
- Consolidated cash, cash equivalents, and marketable securities totaled $4.3 billion as of March 31, 2026.
- Q4 income from continuing operations, net of tax, was $355.7 million, compared to a $252.4 million loss in prior year.
- IMVT-1402 showed 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16 in D2T RA trial.
- Brepocitinib granted Breakthrough Therapy Designation for cutaneous sarcoidosis based on positive Phase 2 data.
- Commercial launch of brepocitinib in dermatomyositis expected by end of September 2026.
- Mosliciguat Phase 2 PHocus study in PH-ILD completed enrollment of 135 subjects.
- R&D expenses increased by $53.7 million to $198.9 million for the three months ended March 31, 2026.
Price Impact
More from ROIV
Roivant Sciences to hold Annual General Meeting on September 16, 2026
Roivant's Brepocitinib gets FDA Priority Review for DM; $2.25B Moderna Settlement
Roivant reaches $2.25B Moderna settlement; IMVT-1402 shows strong D2T RA data